Phuturdex › Diseases › Acute myeloid leukemia
Drugs in development · updated 30 October 2026
Acute myeloid leukemia: drugs in development
As of 30 October 2026 there are 573 active clinical trials (recruiting or ongoing, phases I–III) on 314 drugs for acute myeloid leukemia. 182 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 182 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VenetoclaxVentoclax, Venclexta® | II–III | 181 | NCT07581002 |
| AzacitidineAzacytidine, 5-azacytidine | II–III | 161 | NCT07581002 |
| CytarabineAra-C, Cytosine Arabinoside | II–III | 109 | NCT07255872 |
| FludarabineFludara, FLUDARABIN | II–III | 89 | NCT04708054 |
| DecitabineDacogen® | II–III | 59 | NCT03793517 |
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 58 | NCT07157514 |
| DaunorubicinDaunomycin, Daunoxome® | II–III | 42 | NCT07255872 |
| BusulfanBusulphan, Busulfex® | II–III | 35 | NCT04708054 |
| IdarubicinIdamycin Pfs®, Idamycin® | II–III | 32 | NCT02416388 |
| MelphalanEvomela®, Hepzato® | III | 29 | NCT05457556 |
| TacrolimusEnvarsus XR, Prograf® | III | 27 | NCT05457556 |
| GilteritinibXospata | II–III | 25 | NCT07425808 |
| Mycophenolate MofetilMycophenolate, Cellcept | III | 23 | NCT05457556 |
| CedazuridineCedaruridine | II–III | 20 | NCT04256317 |
| IvosidenibAG-120, Tibsovo® | III | 19 | NCT03839771 |
Sorted by most advanced phase and number of active trials. Showing 15 of 132 drugs.
All 314 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Acute promyelocytic leukemia 8 drugs
- Leukemia 153 drugs
- Myeloid leukemia 26 drugs
- Acute monocytic leukemia 22 drugs
- Acute biphenotypic leukaemia 80 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Blastic plasmacytoid dendritic cell neoplasm 24 drugs
- GATA2 deficiency 18 drugs
- Burkitt lymphoma 113 drugs
- Mast cell leukemia 7 drugs
- Myeloproliferative disorders 91 drugs
- Neoplasm 671 drugs
Broader categories
- Hematologic Diseases 57 drugs
- Neoplasm 671 drugs
- Myeloid leukemia 26 drugs
- Leukemia 153 drugs
- Bone marrow disease 14 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015470 “Leukemia, Myeloid, Acute”. Prevalence: Orphanet.